Rapid, robust and sustained antiviral response with once-daily (QD) dolutegravir (DTG, S/GSK1349572), a next generation integrase inhibitor (INI) in combination therapy in antiretroviral-naïve adults: 48 week results from SPRING-1 (ING112276)

TUAB0102

---

Time: 11:15
Speaker: Jan van Lunzen

You can download the mp3 file here

For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.